Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
3 December 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (the "**Fosun Pharma Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**") received the approval from the National Medical Products Administration for the clinical trial of FXS887 Tablets (project code and hereinafter referred to as "**FXS0887**") for the treatment of advanced malignant solid tumors. Fosun Pharma Industrial intends to commence the Phase I clinical trial of the FXS0887 in China[1] when the conditions are fulfilled.

II. Basic Information and Research Progress on FXS0887

FXS0887 is an orally small molecule innovative drug independently developed by the Group (i.e., the Company and its subsidiaries/units, the same applies below), which is intended to be used for the treatment of advanced malignant solid tumors. FXS0887 specifically inhibits ATR (Ataxia Telangiectasia and Rad3-related) kinase activity, suppressing the malignant proliferation of tumor cells by interfering with cell cycle regulation and DNA damage repair pathways. Preclinical studies conducted to date have demonstrated that FXS0887 exhibits significant anti-tumor efficacy across various tumor models, with low off-target risk and favorable safety profiles.

[1] excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below.

As of October 2025, the Group has invested approximately RMB44 million (unaudited) in total in the research and development ("**R&D**") of FXS0887 at this stage.

As of the date of this announcement (i.e., 3 December 2025), no monotherapy or combination therapy regimens of small molecule inhibitor with the same target has been approved for marketing worldwide.

III. Impact on the Listed Company and Risk Warning

As required by the relevant laws and regulations in China, the FXS0887 is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

3 December 2025

*For identification purpose only